pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include Asthma, Idiopathic pulmonary fibrosis (IPF), Mild to moderate asthma, Pulmonary fibrosis, Chronic obs
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT HQ
6,080 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
- Employees
- 6,080
- Programs
- 20
- Drugs
- 38
- Patents
- 0
0.9% sodium chloride aqueous solution for IV infusion
Phase 2 · small molecule · Idiopathic pulmonary fibrosis (IPF)
0.9% sodium chloride aqueous solution for IV infusion for Idiopathic pulmonary fibrosis (IPF) is a Phase 2 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Internal code CLI-10067AA1-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chiesi Farmaceutici S.p.A
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Idiopathic pulmonary fibrosis (IPF)
- Status
- active
- Trials
- 1